Cristina Guarducci, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptor, erbB-2 | 7 | 2024 | 2370 | 0.420 |
Why?
|
Receptors, Estrogen | 9 | 2024 | 2183 | 0.410 |
Why?
|
Piperazines | 4 | 2024 | 2480 | 0.370 |
Why?
|
Cyclin-Dependent Kinase 6 | 3 | 2021 | 322 | 0.350 |
Why?
|
Pyridines | 4 | 2024 | 2810 | 0.330 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2021 | 528 | 0.330 |
Why?
|
Breast Neoplasms | 12 | 2024 | 20676 | 0.320 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2016 | 1497 | 0.220 |
Why?
|
Carcinoma, Lobular | 1 | 2022 | 482 | 0.160 |
Why?
|
Genes, Retinoblastoma | 1 | 2018 | 136 | 0.160 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2022 | 1100 | 0.130 |
Why?
|
NF-kappa B | 1 | 2023 | 2502 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 5502 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 909 | 0.120 |
Why?
|
Retinoblastoma Protein | 1 | 2016 | 700 | 0.110 |
Why?
|
Estradiol | 2 | 2016 | 2021 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2022 | 5148 | 0.090 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 13635 | 0.070 |
Why?
|
Tamoxifen | 2 | 2022 | 978 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11410 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2021 | 97 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1157 | 0.040 |
Why?
|
Antigen Presentation | 1 | 2023 | 1286 | 0.040 |
Why?
|
Mitochondrial Proteins | 1 | 2023 | 989 | 0.040 |
Why?
|
Female | 12 | 2024 | 378853 | 0.040 |
Why?
|
E2F2 Transcription Factor | 1 | 2016 | 38 | 0.040 |
Why?
|
Cell Count | 1 | 2021 | 1833 | 0.040 |
Why?
|
Postmenopause | 2 | 2016 | 2456 | 0.040 |
Why?
|
E2F1 Transcription Factor | 1 | 2016 | 191 | 0.030 |
Why?
|
Receptors, Progesterone | 1 | 2021 | 1094 | 0.030 |
Why?
|
Transcription Factor AP-2 | 1 | 2016 | 82 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 169 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2016 | 163 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2303 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2024 | 2933 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2023 | 16646 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2016 | 706 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2901 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2021 | 6310 | 0.030 |
Why?
|
Humans | 12 | 2024 | 739398 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2021 | 1849 | 0.030 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3508 | 0.020 |
Why?
|
Aromatase Inhibitors | 1 | 2015 | 490 | 0.020 |
Why?
|
Chromatin | 1 | 2022 | 2848 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 9387 | 0.020 |
Why?
|
ROC Curve | 1 | 2018 | 3526 | 0.020 |
Why?
|
Prognosis | 2 | 2022 | 28901 | 0.020 |
Why?
|
Apoptosis | 1 | 2023 | 9714 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2688 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6871 | 0.020 |
Why?
|
Signal Transduction | 2 | 2021 | 23355 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 4832 | 0.020 |
Why?
|
Disease Progression | 1 | 2021 | 13237 | 0.020 |
Why?
|
Survival Analysis | 1 | 2016 | 10247 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2018 | 10961 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2021 | 62693 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2016 | 11985 | 0.010 |
Why?
|
Middle Aged | 2 | 2018 | 212863 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2018 | 57650 | 0.010 |
Why?
|
Mutation | 1 | 2016 | 29658 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 56255 | 0.010 |
Why?
|
Animals | 1 | 2020 | 168368 | 0.010 |
Why?
|
Aged | 1 | 2018 | 162698 | 0.000 |
Why?
|
Adult | 1 | 2018 | 213394 | 0.000 |
Why?
|